jueves, 12 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 2, 2020

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HEXO, Prudential Financial, Fiat Chrysler, and Merit Medical Systems and Encourages Investors to Contact the Firm

View original at globenewswire.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HEXO, Prudential Financial, Fiat Chrysler, and Merit Medical Systems and Encourages Investors to Contact the Firm NEW YORK, Jan…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Prudential was not over-reserved, but instead its reported reserves, particularly for the Individual Life business segment, were insufficient to satisfy its future policy benefits liabilities

    80% confidence
  • HEXO was cultivating cannabis at its facility in Niagara, Ontario that was not appropriately licensed by Health Canada

    80% confidence
  • Changes in mortality assumptions had negatively impacted the Company's results and would trim near-term momentum

    80% confidence
  • Second quarter 2019 revenue reductions attributed to slower than anticipated conversion and uptake of acquired products

    80% confidence
  • HEXO defendants failed to disclose that reported inventory was misstated as company was failing to write down or write off obsolete product that no longer had value

    80% confidence
  • The integrations of Cianna and Vascular Insights, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule

    80% confidence
  • Change in mortality assumptions would require a negative earnings impact of $25 million per quarter for the foreseeable future, wiping out approximately one third of the earnings attributable to the Individual Life business segment

    80% confidence
  • 2020 guidance off the table until they had reasonable confidence in their forecasting ability

    80% confidence
  • The alleged bribery scheme was authorized at the highest levels of Fiat Chrysler, including the Company's late Chief Executive Officer Sergio Marchionne

    80% confidence
  • Prudential's reserve assumptions failed to account for adversely developing mortality experience in its Individual Life business segment

    80% confidence
  • HEXO was engaging in channel-stuffing in order to inflate its revenue figures and meet or exceed revenue guidance provided to investors

    80% confidence
  • Sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during fiscal 2019

    80% confidence
  • Fiat Chrysler corrupted collective bargaining agreements between GM and UAW in 2009, 2011, and 2015 by paying millions in dollars in bribes

    80% confidence
  • Many operational failures were due to their own overestimation and forecasting

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,565 documentos fuente archivados
Consulta estos datos → isubstrate.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HEXO, Prudential Financial, Fiat Chrysler, and Merit Medical Systems and Encourages Investors to Contact the Firm — Source | Via News | es.VIA.NEWS